AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
186.07
+1.78 (+0.97%)
At close: 4:00PM EDT

186.07 0.00 (0.00%)
After hours: 5:15PM EDT

Stock chart is not supported by your current browser
Previous Close184.29
Open184.19
Bid183.50 x 800
Ask0.00 x 800
Day's Range184.19 - 186.52
52 Week Range142.81 - 223.04
Volume2,379,687
Avg. Volume1,675,671
Market Cap63.16B
Beta1.37
PE Ratio (TTM)N/A
EPS (TTM)-5.32
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & Yield2.88 (1.52%)
Ex-Dividend Date2018-08-16
1y Target Est211.58
Trade prices are not sourced from all markets
  • A Review of Pharma Stocks’ EPS Growth Rates
    Market Realist13 hours ago

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Benzingayesterday

    JMP: Changing Competitive Landscape Makes Revance Less Appealing

    Revance Therapeutics Inc (NASDAQ: RVNC ), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities. The Analyst Analyst Donald Ellis downgraded ...

  • These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
    Market Realistyesterday

    These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018

    The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.

  • Allergan Frown Lines Study Passes Test on Higher Botox Dose
    Zacks2 days ago

    Allergan Frown Lines Study Passes Test on Higher Botox Dose

    Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.

  • PR Newswire4 days ago

    Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines

    DUBLIN, Sept. 14, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced clinical study results of higher doses of BOTOX® Cosmetic compared to BOTOX® Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines.

  • FDA plans meeting to discuss safety data on breast implants
    Associated Press4 days ago

    FDA plans meeting to discuss safety data on breast implants

    U.S. health regulators say they'll convene a public meeting of medical advisers next year to discuss new science on breast implant safety, including an independent analysis that suggests certain rare health problems might be more common with silicone gel implants.

  • PR Newswire4 days ago

    Allergan Highlights Key Growth Drivers for Medical Aesthetics

    DUBLIN, Sept. 14, 2018 /PRNewswire/ -- Allergan plc (AGN) today hosted its first ever Medical Aesthetics Analyst Day where the Company outlined its industry-leading portfolio and pipeline and key initiatives to drive future growth, as well as presented an overview of the global medical aesthetics market.

  • Allergan says revenue from aesthetics unit may double by 2025
    Reuters4 days ago

    Allergan says revenue from aesthetics unit may double by 2025

    Allergan Plc (AGN.N) said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox. The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox. Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc (RVNC.O) and Evolus Inc (EOLS.O) vie to wrest market share with rival treatments to Botox.

  • Allergan says revenue from aesthetics unit may double by 2025
    Reuters4 days ago

    Allergan says revenue from aesthetics unit may double by 2025

    The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox. Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc and Evolus Inc vie to wrest market share with rival treatments to Botox. The company made the announcements at its Medical Aesthetics Day in New York.

  • The Wall Street Journal4 days ago

    [$$] The Curious New Botox Ads

    ’s 2008 hit, “I Kissed a Girl.” Potential customers viewing the ad likely won’t need any medical treatment to raise their eyebrows. The ad fits with Allergan’s effort to boost sales of Botox by marketing it to younger people and to men.

  • Who Really Owns Allergan plc (NYSE:AGN)?
    Simply Wall St.4 days ago

    Who Really Owns Allergan plc (NYSE:AGN)?

    A look at the shareholders of Allergan plc (NYSE:AGN) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...

  • The Wall Street Journal5 days ago

    [$$] Allergan Acquires Neurotoxins Startup Bonti

    Allergan PLC said Friday it would acquire neurotoxin product developer Bonti Inc. for an up-front payment of $195 million.

  • Is Allergan (AGN) a Great Stock for Value Investors?
    Zacks5 days ago

    Is Allergan (AGN) a Great Stock for Value Investors?

    Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.

  • PR Newswire5 days ago

    Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

    DUBLIN and NEWPORT BEACH, Calif., Sept. 14, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti's pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development, EB-001A (aesthetic) and EB-001T (therapeutic).

  • Allergan Unveils Spotlyte, Its First Digital Ventures Launch
    Market Realist5 days ago

    Allergan Unveils Spotlyte, Its First Digital Ventures Launch

    On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. Spotlyte is an innovative digital hub designed to educate consumers about medical aesthetic treatments. The below chart lists key updates on Spotlyte. Spotlyte is the first venture from Project Moonwalker and is designed to educate consumers about medical aesthetics.

  • Why Bausch Health Companies Inc. Stock Is Booming Today
    Motley Fool6 days ago

    Why Bausch Health Companies Inc. Stock Is Booming Today

    Settlement of patent litigation provides a spark for Bausch Health.

  • PR Newswire7 days ago

    Allergan Unveils Spotlyte™, A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments

    DUBLIN, Sept. 12, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced the launch of Spotlyte™ – an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines. Beyond the editorial, Spotlyte will provide access to a team of trained specialists ready to offer real-time support and chat directly with anyone considering medical aesthetic treatments, as well as help connect readers to local licensed providers. Led by Alexandra Wilkis Wilson, co-founder of Gilt Groupe® and Glamsquad®, and appointed senior vice president of Consumer Strategy and Innovation at Allergan, Spotlyte is the first venture from the new Allergan-owned digital ventures unit, Project Moonwalker™.

  • 56% of Analysts Recommend a ‘Buy’ for Editas Medicine
    Market Realist8 days ago

    56% of Analysts Recommend a ‘Buy’ for Editas Medicine

    In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.

  • PR Newswire9 days ago

    Allergan to Host Medical Aesthetics Day Event on September 14, 2018

    DUBLIN , Sept. 10, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it will host a Medical Aesthetics Day event and webcast on Friday, September ...

  • The Wall Street Journal9 days ago

    Cheap Custom-Made Versions of High-Cost Drugs Spur Backlash

    A new kind of drugmaker is emerging to meet demand for lower-priced medicines by custom-making drugs, sparking pushback from federal health regulators and legal challenges from traditional pharmaceutical companies. Companies selling custom-made versions of costly drugs—a practice known as “compounding”—say they are meeting demand for alternatives to high-priced drugs. Athenex Inc. in Buffalo, N.Y., last month began marketing a compounded alternative to blood-pressure medication Vasostrict, which the company said it sells for up to 35% less than the branded version.

  • Benzinga9 days ago

    Insider Buys Of The Week: Allergan, American Homes 4 Rent, Tiffany

    Conventional wisdom says that insiders and 10-percent owners only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. American Homes 4 Rent (NYSE: AMH) saw two directors step up to the buy window this past week. Shares of American Homes 4 Rent were hitting new 52-week highs as August came to a close.

  • GuruFocus.com9 days ago

    Top Insider Buys Highlight for the Week of Sept. 7

    The largest Insider Buys this week were for American Express Co. (AXP), Schlumberger Ltd. (SLB), Allergan PLC (AGN) and Keurig Dr Pepper Inc.

  • Allergan Launches the SkinMedica Lumivive System
    Market Realist11 days ago

    Allergan Launches the SkinMedica Lumivive System

    On September 6, Allergan (AGN) announced the launch of its new innovative dual-acting product, the SkinMedica Lumivive System. Lumivive is an innovative skincare product that works as a shield from blue light during the day and an essential skin repair process at night. The Lumivive System offers atmospheric protection during the day and fights the signs of aging for optimal skin health.

  • Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
    Market Realist12 days ago

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.